<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117559</url>
  </required_header>
  <id_info>
    <org_study_id>F3332-P</org_study_id>
    <nct_id>NCT00117559</nct_id>
  </id_info>
  <brief_title>Improving Quality of Life for Veterans Undergoing Interferon Treatment</brief_title>
  <official_title>Improving Quality of Life for Veterans Undergoing Interferon Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a group psychotherapy intervention and a telehealth
      intervention for veterans undergoing interferon treatment for the hepatitis C virus. It is
      hypothesized that the cognitive behavioral therapy (CBT) condition and the telehealth
      condition will result in significantly improved outcomes, including enhanced adherence,
      quality of life, and psychological status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the proposed pilot study is to evaluate a rehabilitative cognitive-behavioral
      group psychotherapy intervention and a telehealth intervention for veterans undergoing
      interferon treatment for the hepatitis C virus (HCV). The specific objectives of the proposed
      pilot study are: 1) develop study methods and materials; 2) evaluate study feasibility; and
      3) assess the efficacy of a cognitive-behavioral group therapy approach and a telehealth
      approach as compared to care as usual in a randomized design. Participants will be 45
      patients (15 participants in each condition) from the VA Boston Healthcare System who are
      undergoing interferon treatment for HCV. Assessment will occur at pre-treatment,
      post-treatment, and 3-month follow-up. Assessments will measure key areas, including
      adherence, quality of life, and psychological distress. Analyses will examine study
      feasibility and the effects of the treatment condition. It is hypothesized that the CBT
      condition and the telehealth condition will result in significantly improved outcomes,
      including enhanced adherence, quality of life, and psychological status. This treatment
      approach addresses initiatives by the National VHA Hepatitis C Program by optimizing the care
      of veterans experiencing the devastating side effects of interferon treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BDI</measure>
    <time_frame>8 weeks</time_frame>
    <description>Beck Depression Inventory - measures depression. Range for Total score = 0 to 63 Higher scores are indicative of increased depression
The Beck Depression Inventory (BDI; Beck &amp; Steer, 1988) is a widely used 21-item self-report instrument designed to assess depressive mood and symptoms. Each item is rated on a 4-point scale ranging from 0 to 3, with higher scores reflecting greater severity of depressive symptoms for the past two weeks. A sample item is &quot;I do not feel sad.&quot; The BDI has demonstrated reliability (split-half reliability coefficient of .93) and validity (correlations with clinician ratings of depression range from .62 to .75; Beck, Steer, &amp; Garbing, 1988). Cronbach's alpha was high for the present sample at both time points (a = .91 and .90).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Depression</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>TEL-CBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telehealth, problem solving based treatment provided over the telephone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Ususal</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group, no treatment provided</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telehealth Treatment</intervention_name>
    <description>Participants receive a 15-minute telephone call for 8 weeks</description>
    <arm_group_label>TEL-CBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of hepatitis C.

          -  Must be on the interferon treatment

          -  Need to have access to telephone.

        Exclusion Criteria:

          -  Life threatening or acute illness

          -  Current alcohol or substance abuse or dependence

          -  Individuals already receiving psychological interventions specifically to manage the
             side effects of the IFN treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Silberbogen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Jamaica Plain Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Jamaica Plain Campus</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>July 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2005</study_first_posted>
  <results_first_submitted>November 17, 2014</results_first_submitted>
  <results_first_submitted_qc>December 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2014</results_first_posted>
  <last_update_submitted>December 9, 2014</last_update_submitted>
  <last_update_submitted_qc>December 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psychotherapy,group</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Telecommunications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TEL-CBT</title>
          <description>Telehealth, problem solving based treatment
Telehealth Treatment: Participants receive a 15-minute telephone call for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Treatment as Usual</title>
          <description>Control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TEL-CBT</title>
          <description>Telehealth, problem solving based treatment
Telehealth Treatment: Participants receive a 15-minute telephone call for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Treatment as Usual</title>
          <description>Control group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.78" spread="4.35"/>
                    <measurement group_id="B2" value="54.50" spread="6.38"/>
                    <measurement group_id="B3" value="54.16" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BDI</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.93" spread="8.17"/>
                    <measurement group_id="B2" value="12.29" spread="10.10"/>
                    <measurement group_id="B3" value="12.61" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BDI</title>
        <description>Beck Depression Inventory - measures depression. Range for Total score = 0 to 63 Higher scores are indicative of increased depression
The Beck Depression Inventory (BDI; Beck &amp; Steer, 1988) is a widely used 21-item self-report instrument designed to assess depressive mood and symptoms. Each item is rated on a 4-point scale ranging from 0 to 3, with higher scores reflecting greater severity of depressive symptoms for the past two weeks. A sample item is “I do not feel sad.” The BDI has demonstrated reliability (split-half reliability coefficient of .93) and validity (correlations with clinician ratings of depression range from .62 to .75; Beck, Steer, &amp; Garbing, 1988). Cronbach’s alpha was high for the present sample at both time points (a = .91 and .90).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TEL-CBT</title>
            <description>Telehealth, problem solving based treatment
Telehealth Treatment: Participants receive a 15-minute telephone call for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>BDI</title>
          <description>Beck Depression Inventory - measures depression. Range for Total score = 0 to 63 Higher scores are indicative of increased depression
The Beck Depression Inventory (BDI; Beck &amp; Steer, 1988) is a widely used 21-item self-report instrument designed to assess depressive mood and symptoms. Each item is rated on a 4-point scale ranging from 0 to 3, with higher scores reflecting greater severity of depressive symptoms for the past two weeks. A sample item is “I do not feel sad.” The BDI has demonstrated reliability (split-half reliability coefficient of .93) and validity (correlations with clinician ratings of depression range from .62 to .75; Beck, Steer, &amp; Garbing, 1988). Cronbach’s alpha was high for the present sample at both time points (a = .91 and .90).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.93" spread="8.17"/>
                    <measurement group_id="O2" value="12.29" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.45" spread="6.03"/>
                    <measurement group_id="O2" value="16.67" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During recruitment and when running subjects</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TEL-CBT</title>
          <description>Telehealth, problem solving based treatment
Telehealth Treatment: Participants receive a 15-minute telephone call for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Treatment as Ususal</title>
          <description>Control group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, all male, no in-person comparison group, reporting bias in self-report measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amy Silberbogen, Ph.D.</name_or_title>
      <organization>VA Boston Healthcare System</organization>
      <phone>857-364-4797</phone>
      <email>amy.silberbogen@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

